News | August 04, 2023
Piramal Pharma posts Q1 FY24 consolidated loss at Rs. 98.58 Cr
The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023
The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
Subscribe To Our Newsletter & Stay Updated
